Oxford Gene Technology (OGT) has launched its new next-generation sequencing (NGS) SureSeq
Myeloid MRD Panel for the detection of ultra-low frequency measurable residual disease (MRD)–associated biomarkers in acute myeloid leukemia (AML). The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. OGT states their SureSeq Myeloid MRD Panel enables the detection of thirteen key AML MRD-associated biomarkers. The new panel content was designed to expand on an OGT customer’s MRD-detection capabilities to deliver a better understanding of the current AML status, and ensures genomic insights are not missed.
Oxford Gene Technology
The post
Myeloid Measurable Residual Panel appeared first on
GEN - Genetic Engineering and Biotechnology News.
